The Chronic Lymphocytic Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
DKK 2016 | Personalised medicine in CLL: Redefining the treatment approach
Michael Hallek
• 25 Feb 2016
At the German Cancer Congress 2016, held in Berlin, Germany, from 24 to 27 February 2016, Michael Hallek, MD, from the University of Cologne, Cologne, Germany, discusses chemotherapy, kinase inhibitors and ongoing research in personalized approaches for the treatment of patients with chronic lymphocytic leukemia.
